March 4, 2021 -- Amunix Pharmaceuticals has raised $117 million in financing to fund the advancement of its lead T-cell engager candidate into the clinic.
AMX-818, the company's lead candidate, is a masked, protease-activated T-cell engager (XPAT) targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors that are preferentially activated in the tumor microenvironment.
The funds will also support Amunix's pipeline of earlier stage XPATs and other masked, protease-activated cytokines (XPACs). The candidates were developed using the company's unstructured polypeptide XTEN polymer technology and have been validated in human cells.
The funding round was led by Viking Global Investors.